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The Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) interacts with the tumor necrosis factor receptor
(TNFR)-associated factor (TRAF) molecules, which are important for LMP1-mediated signaling. Two domains of LMP1 can
independently activate NF-kB, carboxyl-terminal activating region 1 (CTAR1) and CTAR2. The activation of NF-kB by CTAR1
occurs through direct interaction of LMP1 with the TRAF molecules, whereas CTAR2 interacts with the TNFR-associated
death domain protein (TRADD) to activate NF-kB and the c-Jun N-terminal kinase (JNK). A20, which is induced by LMP1
through NF-kB, can block NF-kB activation from both domains of LMP1 and inhibit JNK activation from CTAR2. A20 also has
been shown to associate with TRAF1 and TRAF2. In this study, an interaction between LMP1 and A20 was detected that was
increased by TRAF2 overexpression. A20 did not affect the association of TRAF1 with TRAF2 but did displace TRAF1 from
the LMP1 complex. The interaction of LMP1 and TRADD was decreased in the presence of A20, and the LMP1-A20
association was decreased by TRADD, suggesting that A20 and TRADD both interact with LMP1 and may compete for
binding. These data indicate that A20 alters the interactions between LMP1 and the TRAF molecules and TRADD, affecting





























Epstein–Barr virus (EBV) is associated with a variety of
ymphoid and epithelial malignancies including Burkitt’s
ymphoma (BL), posttransplant lymphoma (PTL), and na-
opharyngeal carcinoma (NPC) (zurHausen et al., 1970;
esgranges et al., 1975; Hanto et al., 1982; Geser et al.,
983; Raab-Traub and Flynn, 1986; Raab-Traub et al.,
987; Katz et al., 1989). Preinvasive lesions related to
PC contain clonal EBV DNA and express latent mem-
rane protein (LMP1) in all abnormal cells, suggesting
hat EBV and LMP1 are important in the development of
PC (Pathmanathan et al., 1995). LMP1 is the only EBV-
ncoded protein able to transform established rodent
ibroblasts and is also essential for transformation of
rimary B lymphocytes (Wang et al., 1985; Kaye et al.,
993). LMP1 induces profound changes in cellular gene
xpression due partly to activation of the NF-kB tran-
cription factor. In lymphocytes, LMP1 induces the ex-
ression of cell-surface markers such as CD21, CD23,
D40, and CD44, cell adhesion molecules ICAM1, LFA1,
nd LFA3, and the anti-apoptotic molecules bcl-2 and
20 (D. Wang et al., 1988; F. Wang et al., 1990; Henderson
t al., 1991; Laherty et al., 1992; Peng and Lundgren,
993; Huen et al., 1995). In epithelial cells, LMP1 induces
xpression of the epidermal growth factor receptor
1 To whom reprint requests should be addressed. Fax: (919) 966-
n673. E-mail: nrt@med.unc.edu.
159EGFR) as well as A20 (Miller et al., 1995). LMP1 and A20
oth protect epithelial cells from p53-mediated apoptosis
nduced by serum withdrawal (Fries et al., 1996).
LMP1 initiates signaling events in part through asso-
iation with the tumor necrosis factor receptor-associ-
ted factors (TRAFs) (Mosialos et al., 1995; Devergne et
l., 1996). In addition to LMP1, the TRAFs interact with the
ytoplasmic domains of the tumor necrosis factor recep-
or (TNFR) superfamily members. The ability of LMP1 to
ransform primary B lymphocytes in vitro is dependent on
nteraction with the TRAFs and clustering of LMP1 in the
lasma membrane (D. Wang et al., 1988a,b; Izumi et al.,
997). The TRAF binding site has been defined further as
mino acids 204–208 of LMP1, with a consensus motif of
ro-X-Gln-X-Thr (with X representing any amino acid) that
lso is present in CD40 and CD30 (Hu et al., 1994;
evergne et al., 1996; Gedrich et al., 1996) The TRAF
nteraction domain, which lies within carboxyl-terminal
ctivating region 1 (CTAR1), is one of the two distinct
omains in LMP1 that are able to activate the NF-kB
ranscription factor (Huen et al., 1995; Mitchell and Sug-
en, 1995). The second domain of LMP1 that can activate
F-kB (CTAR2) is located within the last 35 amino acids
nd can interact with the adaptor protein TNFR-associ-
ted death domain protein (TRADD) (Izumi and Kieff,
997). Although direct interactions have not been de-
ected between CTAR2 and the TRAF molecules, NF-kB
ctivation by this domain can be decreased by a domi-
ant negative TRAF2 protein as well as the TRAF inhib-
0042-6822/99 $30.00
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160 FRIES, MILLER, AND RAAB-TRAUBtor TANK (Kaye et al., 1996). The CTAR2 domain also
ctivates c-Jun N-terminal kinase (JNK) (Eliopoulos et al.,
999). A20 blocks the activation of JNK and NF-kB by
MP1 through a previously undetermined mechanism
Eliopoulos et al., 1999).
Expression of the EBV LMP1 protein in epithelial cells
rotected cells from p53-mediated apoptosis in the
1299 cell line containing a temperature-sensitive form
f p53 (Fries et al., 1996). The antiapoptotic protein A20
as induced by LMP1 in this cell line and expression of
20 alone without LMP1 also protected from apoptosis
ediated by p53. Induction of A20 by LMP1 therefore
ay underlie the ability of LMP1 to protect EBV-infected
pithelial cells from p53-mediated apoptosis. However,
ittle is known about how A20 functions. A20 interacts
ith TRAF1, and this interaction is strengthened by ex-
ression of TRAF2, suggesting that A20 associates with
RAF1/TRAF2 heterodimers (Song et al., 1996). TRAF2 is
ble to mediate NF-kB activation by the TNFR type I
TNFRI), TNFRII, EBV LMP1, and CD40 (Rothe et al., 1995;
su et al., 1996). LMP1 also can interact with the TRAF
olecules, with the molar ratios of TRAF1, TRAF2, and
RAF3 present in the LMP1-TRAF complex affecting sig-
aling pathways (Mosialos et al., 1995; Devergne et al.,
996; Miller et al., 1997, 1998). In this study, potential
nteractions between LMP1 and A20 were investigated.
hese data indicate that A20 associates with the LMP1-
RAF and LMP1-TRADD complexes, displacing TRAF1
nd TRADD. The alteration of TRAF complex formation by
20 is likely responsible for its inhibition of LMP1 acti-
ation of JNK and NF-kB.
RESULTS
BV LMP1 is able to interact with A20
n the H1299-p53 cell line
A yeast two-hybrid screen using the LMP1 carboxyl-
erminus identified an interaction with TRAF3 (Mosialos
t al., 1995). Subsequent experiments demonstrated that
RAF1, TRAF2, and TRAF3 constitutively associate with
FIG. 1. Interaction of EBV LMP1 with A20. The H1299-p53 cell line
mmunoprecipitation with c-myc monoclonal antibody agarose conju
mmunoblotting with an LMP1 monoclonal antibody. Direct loads of 1%
xpression. CB5 is an EBV-infected lymphoblastoid cell line included aMP1 in EBV-transformed lymphoblastoid cell lines (De- iergne et al., 1996). Yeast two-hybrid analysis also iden-
ified A20 as a binding partner for TRAF1 and TRAF2
Song et al., 1996), and a direct interaction between
RAF1 and A20 was detected in vivo. An interaction
etween TRAF2 and A20 was not detected although
verexpression of TRAF2 increased the interaction be-
ween TRAF1 and A20. This suggested that perhaps A20
nteracts with TRAF1-TRAF2 heterodimers (Song et al.,
996). To determine whether A20 could directly interact
ith LMP1, LMP1 was tagged with the FLAG epitope and
20 with a c-myc epitope to facilitate immune precipita-
ion. H1299-p53 cells were transfected with LMP1 alone,
s a negative control, or with LMP1 and A20 followed by
mmunoprecipitation of A20 (Fig. 1). Immunoblot analysis
f the total lysate indicated that LMP1 was expressed at
qual levels in both sets of transfected cells; however, it
as only detected in the A20-immune complexes. The
recipitation of LMP1 with A20 suggests that LMP1 spe-
ifically associates with A20.
he effect of TRAF1 and TRAF2 on the LMP1
nd A20 interaction
Expression of TRAF2 has been shown to increase the
ssociation of TRAF1 with A20; therefore, the effect of
xpression of the TRAF molecules on the association of
MP1 with A20 was determined. H1299-p53 cells were
ransfected with LMP1 and A20 and either TRAF1 or
RAF2. The lysates were immunoprecipitated for A20,
nd LMP1 was analyzed in the immune complexes by
mmunoblot analysis. Overexpression of TRAF2 signifi-
antly increased the LMP1-A20 interaction (Fig. 2A). This
ncrease in the LMP1-A20 interaction was specific for
RAF2, and overexpression of TRAF1 did not significantly
r consistently affect the interaction of LMP1 and A20.
The effect of the TRAF molecules on the LMP1-A20
nteraction was confirmed by LMP1 immunoprecipitation
rom transfected lysates. Immunoblot analysis of the in-
ividual transfections detected equal amounts of A20 in
ach lysate, and equal amounts of LMP1 were detected
ransfected with either LMP1 alone or LMP1 and c-myc-tagged A20.
as performed to immunoprecipitate c-myc-tagged A20, followed by
amples were taken before immunoprecipitation to verify LMP1 protein
sitive control for LMP1.was t
gate w









































































161A20 INTERACTS WITH EBV LMP1mmunoblot analysis for A20 confirmed that LMP1 and
20 interact in vivo and that TRAF2 but not TRAF1 ex-
ression increased the interaction between LMP1 and
20 (Fig. 2B). The ability to detect the interaction of LMP1
nd A20 by immunoprecipitating either protein provides
trong evidence for the interaction of these proteins.
urthermore both approaches revealed that TRAF2 en-
ances this association.
ffect of A20 expression on the interaction of TRAF1
nd TRAF2 with LMP1
To determine whether A20 binding to LMP1 affected
MP1 association with TRAF molecules, duplicate plates
FIG. 2. Effect of TRAF1 and TRAF2 on the interaction of EBV LMP1
ith A20. (A) The H1299-p53 cell line was transfected with FLAG-
agged LMP1 and A20 plus either TRAF1 or TRAF2 as indicated. The
ysates were immunoprecipitated with an A20 monoclonal antibody,
nd the immune complexes were analyzed by immunoblot analysis
ith an LMP1 monoclonal antibody. (B) H1299-p53 cells were trans-
ected with c-myc-tagged A20 and FLAG-tagged LMP1 in addition to
RAF1 or TRAF2 where indicated. Direct loads of 1% of the samples
ere taken before mmunoprecipitation to verify equal expression of
20. Immunoprecipitation was performed with FLAG beads, followed
y immunoblot analysis with an LMP1 monoclonal antibody to deter-
ine equivalent immunoprecipitation. A20 was detected in the immune
omplexes with a c-myc monoclonal antibody.f H1299-p53 cells were transfected with LMP1, TRAF1, wnd TRAF2, either with or without A20. LMP1 immuno-
recipitation was followed by immunoblotting for A20,
RAF1, TRAF2, or LMP1 (Fig. 3). Aliquots of whole cell
xtracts were taken before immunoprecipitation to con-
rol for equal protein expression and to determine the
xtent of binding. LMP1 was equally expressed in the
ell lysates with and without A20, and equal amounts of
MP1 were immunoprecipitated (Fig. 3). Confirming pre-
ious studies, a significant proportion of TRAF1 was
ssociated with LMP1. Although only trace amounts of
20 bind to LMP1, in the presence of A20 the interaction
f TRAF1 with LMP1 was dramatically decreased to ;1%
f the total TRAF1. In contrast, detection of TRAF2 indi-
ated that ;2% of the TRAF2 was bound to LMP1 in the
bsence of A20 and that overexpression of A20 slightly
ecreased this association of TRAF2 with LMP1.
he effect of A20 on the association of TRAF1/TRAF2
Overexpression of TRAF2 can activate NF-kB, and
RAF1 and TRAF2 exist in complexes that are not asso-
iated with membrane-bound receptors. As previous
tudies have indicated that A20 binds to TRAF1/TRAF2
eterodimers, it was of interest to determine whether
20 affected the binding of TRAF1 to TRAF2. Cells were
ransfected with TRAF1 and TRAF2 with or without A20.
mmunoprecipitation of TRAF1 followed by immunoblot
nalysis for TRAF2 indicated that TRAF2 is associated
ith TRAF1 and that A20 overexpression does not affect
his association (Fig. 4).
MP1 interferes with the A20–TRAF2 interaction
To determine whether LMP1 affected the interaction of
20 with TRAF1/TRAF2 complexes, cells were trans-
ected with A20 and TRAF2. The association of A20 with
RAF2 then was determined in the presence or absence
f LMP1. Although previous studies did not detect a
irect interaction between TRAF2 and A20, in these stud-
es, ;2% of the TRAF2 protein in the cell was detected in
he A20 immune complex (Fig. 5). Equal amounts of A20
ere detected in the immunoprecipitated complexes;
owever, the amount of TRAF2 that interacted with A20
ecreased to ;0.2% in the presence of LMP1. This sug-
ests TRAF2 has a greater affinity for LMP1 than for A20.
he effect of A20 on LMP1–TRADD and TRADD on
MP1–A20 interactions
The TRADD adaptor molecule is able to interact with
he CTAR2 domain of LMP1 and is thought to mediate the
ctivation of NF-kB by CTAR2. This CTAR2-mediated ac-
ivation is decreased by inhibitors of TRAF2-mediated
F-kB activation, including TANK/I-TRAF, and by a dom-
nant negative form of TRAF2 (Cheng and Baltimore,
996; Kaye et al., 1996; Eliopoulus et al., 1997; Izumi and
ieff, 1997). As A20 also inhibits signaling from CTAR2, it





































162 FRIES, MILLER, AND RAAB-TRAUBssociation of LMP1 with TRADD. H1299-p53 cells were
ransfected with LMP1 and TRADD with or without A20.
mmunoprecipitation of LMP1 followed by immunoblot
nalysis with a TRADD antibody confirmed that LMP1
nteracts with TRADD (Fig. 6A). This interaction did not
ccur with a previously described mutation in the TRADD
nteracting domain in LMP1, 383-ID, that blocks TRADD
inding. Coexpression of A20 decreased the interaction
f LMP1 with TRADD although some TRADD was de-
ected after longer exposure (data not shown).
The effect of TRADD on the LMP1–A20 interaction also
as investigated. Cells were transfected with LMP1 and
20 with or without TRADD. Immunoprecipitation for
MP1 followed by immunoblotting for LMP1, A20, and
RADD detected approximately equivalent amounts of
MP1 in the immunoprecipitated complexes (Fig. 6B).
20 was readily detected in the precipitated complex,
onfirming the interaction of LMP1 and A20 (Fig. 6B).
RADD expression decreased but did not eliminate the
inding of LMP1 and A20. These data suggest that
RADD and A20 compete for binding to the LMP1 CTAR2
omain. The residual binding of A20 to LMP1 in the
resence of overexpressed TRADD most likely reflects
FIG. 3. Effect of A20 expression on the interaction of TRAF1 and T
LAG-tagged LMP1, TRAF1, or TRAF2 or with the addition of c-myc-tagg
nd immunoblotted with the c-myc monoclonal antibody to detect c-my
onoclonal antibody. The direct load samples were taken prior to im
mmunoprecipitations shown above.he binding of A20 to the TRAF domain in CTAR1, which tould not be affected by TRADD overexpression. The
nteraction of A20 with the LMP1 TRADD domain was
onfirmed by immunoprecipitation of A20 with LMP1 that
ith LMP1. Duplicate plates of H1299-p53 cells were transfected with
as indicated. The lysates were immunoprecipitated with FLAG beads
d A20, TRAF1 rabbit antisera, TRAF2 rabbit antisera, or the S12 LMP1
recipitation and represent 2, 1, and 0.5% of the total lysate used for
FIG. 4. Interaction of TRAF1 and TRAF2 in the presence and absence
f A20. The H1299-p53 cell line was transfected with FLAG-tagged
RAF1 and TRAF2 with or without A20, as indicated. Lysates were
mmunoprecipitated with FLAG beads, followed by immunoblot analy-
is with a TRAF2 rabbit polyclonal antibody. The direct load samples
ere taken prior to immunoprecipitation and represent 2, 1, and 0.5% of
he total lysate used for the immunoprecipitations shown above con-RAF2 w
ed A20
c-tagge



























































163A20 INTERACTS WITH EBV LMP1s deleted for the TRAF interacting motif at amino acids
04–208 (data not shown).
DISCUSSION
In this study, we present evidence that A20 and LMP1
xist in a complex in vivo. The interaction of A20 with
MP1 significantly affects the LMP1/TRAF complex with
isplacement of TRAF1 and perhaps a small amount of
RAF2 by A20. It is known that A20 blocks LMP1 CTAR1-
ediated NF-kB activation, and this effect is likely
aused by the displacement of TRAF1 from LMP1 by A20.
he displacement of TRAF1 from the LMP1–TRAF com-
lex by A20 would block the ability of TRAF1 to coacti-
ate TRAF2-mediated NF-kB activation by the CTAR1
omain of LMP1 (Devergne et al., 1996). Similarly, A20
locks the activation of both NF-kB and JNK by CTAR2
Eliopoulos et al., 1999). The activation of NF-kB and JNK
y CTAR2 is mediated by the adaptor molecule TRADD,
nd the data presented here indicate that both A20 and
RADD can interact with LMP1 and may compete for
inding. This negative regulation of LMP1 signaling from
oth CTAR1 and CTAR2 by A20 may be an important
eedback loop to modulate the levels of activated NF-kB
nd JNK in the infected cell.
Although A20 and TRADD seem to directly compete for
inding to LMP1, the effects of A20 on TRAF1 binding are
ess direct and are modulated by TRAF2. Only ;2% of the
RAF2 is associated with LMP1 and 2% of TRAF2 with
FIG. 5. Interaction of A20 and TRAF2 in the presence and absence o
20, TRAF2, and FLAG-tagged LMP1 as indicated. Lysates were prepa
aken for immunoblot analysis. The direct loads represent 2, 1, and
mmunoprecipitation. (B) H1299-p53 cells were transfected with the ind
garose conjugate to immunoprecipitate c-myc-tagged A20. The immu
qual amounts of A20 in the immunoprecipitated complexes and the am20. This excess of TRAF2 would predict that the expres- cion of LMP1 or A20 would not affect the association of
RAF2 with other molecules, and A20 did not affect the
ssociation of TRAF1 with TRAF2. In contrast, although
RAF2 increased the binding of A20 to LMP1, LMP1
ramatically decreased the A20–TRAF2 interaction. This
uggests that LMP1 may interact with TRAF2/A20 com-
lexes. TRAF2 apparently has a greater affinity for direct
inding to LMP1 than to A20 such that in the presence of
MP1, A20 is displaced from TRAF2 but now binds di-
ectly to LMP1, displacing TRAF1. Importantly, these ef-
ects of A20 on the constituents of the LMP1/TRAF/
RADD complexes suggest that at least two different
orms of LMP1 complexes exist: one that contains TRAF1
nd TRADD in addition to other TRAFs and a second that
ontains A20 and TRAFs (Fig. 7). Interestingly, LMP1
nduces the expression of both TRAF1 and A20 (Laherty
t al., 1992; Devergne et al., 1998). A20 is induced inde-
endently by either CTAR1 or CTAR2 of LMP1 through
he NF-kB transcription factor. In contrast, induction of
RAF1 expression, similarly to LMP1-induced expres-
ion of the EGFR, is mediated only through CTAR1 and is
ependent on the direct interaction of the TRAF mole-
ules with the CTAR1 domain of LMP1 (Devergne et al.,
998; Miller et al., 1998). The TRAF1/TRAF2-containing
MP1 complexes would activate NF-kB and induce ex-
ression of A20 (Fig. 7). A20 would bind to LMP1, dis-
lace TRAF1 and TRADD, and decrease the levels of
ctivated NF-kB in the cell. A20 could also directly bind to
LMP1. (A) The H1299-p53 cell line was transfected with c-myc-tagged
d before immunoprecipitation, aliquots of the whole cell lysates were
f the total lysate containing A20, TRAF2, and LMP1 used in (B) for
DNAs, and immunoprecipitation analysis was performed using c-myc
plexes were analyzed using the c-myc monoclonal antibody to verify













































































164 FRIES, MILLER, AND RAAB-TRAUBctivity. In the absence of activated NF-kB, A20 expres-
ion would decrease, enabling TRAF1 and TRADD to
gain bind to LMP1.
It is also possible that the A20-containing LMP1 com-
lex may positively activate cellular gene expression and
ould induce expression of other genes, such as TRAF1.
he distinct LMP1 complexes may coexist, perhaps in
ifferent cellular compartments, or be temporally regu-
ated. The binding of TRAF1 or A20 could also differen-
ially regulate signaling from CTAR1 and CTAR2. LMP1,
FIG. 6. The effect of A20 and TRADD on their interactions with EBV
MP1. (A) H1299-p53 cells were transfected with FLAG-tagged LMP1,
RADD, FLAG-tagged LMP1 mutant 383-ID, or c-myc-tagged A20
here indicated. Lysates then were immunoprecipitated with FLAG
eads to immunoprecipitate FLAG-tagged LMP1 or FLAG-tagged 383-
D. The amount of TRADD in the immune complexes was determined
y immunoblot analysis with a TRADD goat polyclonal antibody. Lysate
rom H1299-p53 cells transfected with TRADD was included as a
ositive control. (B) The H1299-p53 cell line was transfected with
LAG-tagged LMP1 and c-myc-tagged A20, with or without TRADD as
ndicated. Immunoprecipitation of FLAG-tagged LMP1 with FLAG
eads was followed by immunoblotting with an LMP1 monoclonal
ntibody to verify equivalent immunoprecipitation and the c-myc mono-
lonal antibody to determine the amount of A20 in the immune com-
lexes. TRADD was detected with a goat polyclonal antibody in the
ells transfected with the TRADD construct.hrough induction of either A20 or TRAF1, could carefully fegulate the level of kB signaling and also modulate
ther TRAF-mediated signaling pathways.
MATERIALS AND METHODS
ell lines
The H1299-p53 cell line is a derivative of the human
on-small-cell lung carcinoma cell line stably expressing
mouse ts-p53 (Fries et al., 1996). The cells were main-
ained at 39°C in Dulbecco’s modified Eagle’s medium
upplemented with 10% fetal bovine serum, penicillin,
treptomycin, and 600 mg of G418 per milliliter (Gibco).
B5 is a human LCL established by infection of cord
lood lymphocytes with B95–8 virus, and BJAB is an
BV-negative high-grade B-cell lymphoma. Lymphoid
ells were maintained in RPMI 1640 medium containing
enicillin and streptomycin, and supplemented with 10%
etal bovine serum.
lasmids and expression vectors
The FLAG-tagged LMP1 expression vector contains
he LMP1 cDNA, with an amino-terminal FLAG se-
uence, cloned into the pcDNA3 vector (Invitrogen) as
reviously described (Miller et al., 1997). The FLAG-
agged LMP1 383-ID mutant was constructed by poly-
erase chain reaction (PCR), as described (Izumi and
ieff, 1997), and cloned into pcDNA3 (Invitrogen). The
20 cDNA was cloned into the EcoRI and XhoI restriction
ites of the pcDNA3 expression vector. The c-myc-
agged A20 expression vector was constructed by PCR
f the BclI/XhoI fragment of A20, using the 59 primer
59-ATCACGAGGCCCCCGCCTGTGATCATTTTGGCAAT-
9) and the 39 primer (59-ATCACGAGCATGGTGGCTC-
AGCGCCATACATCTGCTT-39), to eliminate the A20 stop
odon. The PCR fragment was ligated to the A20 EcoRI/
clI fragment and subcloned into the EcoRI and XhoI
estriction sites of the pA3M expression vector (a deriv-
tive of pcDNA3, kindly provided by Erle Robertson),
ositioning the A20 cDNA in frame with three copies of
he c-myc epitope at the carboxyl-terminus (Aster et al.,
997). The A20 sequence was confirmed by DNA se-
uencing at the UNC-CH automated DNA sequencing
acility on a model 377 DNA sequencer (Perkin–Elmer,
pplied Biosystems Division) using the ABI PRISMDye
erminator cycle sequencing ready reaction kit with Am-
liTaq DNA Polymerase (Perkin–Elmer, Applied Biosys-
ems Division). FLAG-TRAF1, TRAF1, TRAF2, and TRAF3
re all subcloned into the pSG5 (Stratagene) expression
ector and were kindly provided by Elliott Kieff. The
RADD cDNA, kindly provided by David Goeddel (Tu-
arik), is under control of the CMV promoter in the
cDNA3 expression vector (Invitrogen).
mmunoprecipitations
Transient transfections were performed using the lipo-

































































165A20 INTERACTS WITH EBV LMP1pecifications as previously reported (Fries et al., 1997). Cell
xtracts were prepared 48 h after transfection, by incuba-
ion at 4°C for 30 min, and then scraping confluent mono-
ayers into 1 ml of lysis buffer (20 mM HEPES, 0.5% N-P40,
50 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM PMSF, 2.5
g/ml Aprotinin, and 25 mg/ml Leupeptin). The whole cell
ysates were subjected to centrifugation, and 20 ml of anti-
LAG M2 affinity gel (Sigma) or 20 ml of anti-c-myc (9E10)
garose conjugate (Santa Cruz) was added to the super-
atants. Samples were nutated overnight at 4°C, washed
ive times with lysis buffer, immune complexes were resus-
ended in 33 sample buffer, and boiled for 10 min.
A20 immunoprecipitations were performed by pre-
FIG. 7. Effect of A20 on the EBV LMP1 signaling complex. (A) A
artoon of EBV LMP1 located in the cell membrane, with the CTAR1
omain interacting with TRAF1 and TRAF2, and the CTAR2 domain
nteracting with TRADD. Both CTAR1 and CTAR2 are able to activate
F-kB, which results in the transcription of many genes, including A20.
RAF2 overexpression also activates NF-kB, indicated by the cytoplas-
ic TRAF1/TRAF2 complex. (B) The A20 protein is able to interact with
RAF1, TRAF2, and LMP1. The addition of A20 to the LMP1-TRAF
omplex significantly decreases the ability of both TRAF1 and TRADD
o interact with LMP1, blocking the continuous activation of NF-kB and
NK by LMP1. A20 also can block NF-kB activation by cytoplasmic TRAF
omplexes. The presence of A20 in the LMP1/TRAF/TRADD complex
lso may result in a positive signal to an unidentified transcription
actor that could activate expression of other genes.learing the supernatants with 30 ml of GammaBind Gepharose (Pharmacia Biotech) nutating for 1 h at 4°C,
dding 5 ml of A20-specific monoclonal antibody, (a gift
rom Vishva Dixit), (Jaattela et al., 1996) to the precleared
upernatant, and nutating for 2 h at 4°C. GammaBind G
epharose was added, samples were nutated for an
dditional 1 h at 4°C, washed five times with lysis buffer,
esuspended in 33 sample buffer, and boiled for 10 min.
mmunoblot analysis
Immune complexes were analyzed by sodium dodecyl
ulfate (SDS) polyacrylamide gel electrophoresis and
hen subjected to immunoblot analysis. Polyacrylamide
els were transferred to a supported nitrocellulose filter
Schleicher and Schuell) with a Hoefer semidry transfer
pparatus. Filters were stained with Ponceau S (Sigma)
o verify equal transfer and blocked overnight in Tris-
uffered saline with 0.1% Tween 20 and 5% nonfat dried
ilk (BLOTTO). The TRAF1, TRAF2, TRADD, and c-myc-
pitope tagged A20 proteins were detected with the
RAF1 (S-19) or TRAF2 (C-20) rabbit polyclonal antibod-
es, the TRADD (C-20) goat polyclonal antibody, or the
-myc (9E10) mouse monoclonal, respectively (Santa
ruz), at a 1:200 dilution. The LMP1 protein was detected
s described previously, using the S12 monoclonal anti-
ody at a 1:10 dilution (Miller et al., 1995). The wild-type
20 protein was detected with an A20-specific monoclo-
al antibody at a 1:500 dilution. Reactivity was detected
sing the appropriate species specific horseradish per-
xidase-conjugated secondary antibodies to mouse or
abbit (Amersham), or to goat (DAKO), at a 1:1000 dilution
nd developed with the enhanced chemiluminescence
eagents according to manufacturer’s specifications
Amersham).
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